187 related articles for article (PubMed ID: 18830928)
21. Patient-specific vaccine therapy for non-Hodgkin lymphoma.
Hohenstein M; King SE; Fiore JM; O'Brien T; Blumel S
Clin J Oncol Nurs; 2005 Feb; 9(1):85-90. PubMed ID: 15751502
[TBL] [Abstract][Full Text] [Related]
22. Future of idiotypic vaccination for B-cell lymphoma.
de Cerio AL; Inogés S
Expert Rev Vaccines; 2009 Jan; 8(1):43-50. PubMed ID: 19093772
[TBL] [Abstract][Full Text] [Related]
23. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.
Hege KM; Jooss K; Pardoll D
Int Rev Immunol; 2006; 25(5-6):321-52. PubMed ID: 17169779
[TBL] [Abstract][Full Text] [Related]
24. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
[TBL] [Abstract][Full Text] [Related]
25. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of idiotype vaccination in relapsed B-cell malignancies.
Inogés S; Rodríguez-Calvillo M; López-Díaz de Cerio A; Zabalegui N; Pérez-Calvo J; Panizo C; Hernandez M; Cuesta B; Rocha E; Bendandi M
Haematologica; 2003 Dec; 88(12):1438-40. PubMed ID: 14688006
[No Abstract] [Full Text] [Related]
27. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
Schumacher K
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
[No Abstract] [Full Text] [Related]
28. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
Reinis M
Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
[TBL] [Abstract][Full Text] [Related]
29. Immune responses and outcome in follicular lymphoma.
Gribben JG
J Clin Oncol; 2014 Jun; 32(17):1757-9. PubMed ID: 24799493
[No Abstract] [Full Text] [Related]
30. A therapeutic vaccine using Salmonella-modified tumor cells combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma.
Grille S; Moreno M; Brugnini A; Lens D; Chabalgoity JA
Leuk Res; 2013 Mar; 37(3):341-8. PubMed ID: 23107422
[TBL] [Abstract][Full Text] [Related]
31. Idiotype vaccine strategies for treatment of follicular lymphoma.
Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
[TBL] [Abstract][Full Text] [Related]
32. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.
Hawkins RE; Russell SJ; Marcus R; Ashworth LJ; Brissnik J; Zhang J; Winter G; Bleehen NM; Shaw MM; Williamson L; Ouwehand W; Stevenson F; Hamblin T; Oscier D; Zhu D; King C; Kumar S; Thompsett A; Stevenson GT
Hum Gene Ther; 1997 Jul; 8(10):1287-99. PubMed ID: 9215745
[No Abstract] [Full Text] [Related]
34. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
35. Vaccination as immunotherapy for B cell lymphoma.
Schultze JL
Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
[TBL] [Abstract][Full Text] [Related]
36. Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma.
Kunkel LA
Cancer Invest; 2004; 22(1):97-105. PubMed ID: 15069767
[No Abstract] [Full Text] [Related]
37. 1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.
Levy R
Biochim Biophys Acta; 1999 Oct; 1424(2-3):R43-4. PubMed ID: 10528154
[No Abstract] [Full Text] [Related]
38. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
Borrello I; Sotomayor EM; Rattis FM; Cooke SK; Gu L; Levitsky HI
Blood; 2000 May; 95(10):3011-9. PubMed ID: 10807763
[TBL] [Abstract][Full Text] [Related]
39. Vaccination strategies in follicular lymphoma.
Kannan S; Neelapu SS
Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
[TBL] [Abstract][Full Text] [Related]
40. Cancer. Fusion potential for vaccines.
Taylor-Papadimitriou J; Balkwill F
Nature; 1993 Apr; 362(6422):695. PubMed ID: 8469278
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
